TW272940B - / - Google Patents

/

Info

Publication number
TW272940B
TW272940B TW082105551A TW82105551A TW272940B TW 272940 B TW272940 B TW 272940B TW 082105551 A TW082105551 A TW 082105551A TW 82105551 A TW82105551 A TW 82105551A TW 272940 B TW272940 B TW 272940B
Authority
TW
Taiwan
Prior art keywords
inactivator
purpura
prophylaxis
medicament
therapy
Prior art date
Application number
TW082105551A
Other languages
English (en)
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Application granted granted Critical
Publication of TW272940B publication Critical patent/TW272940B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
TW082105551A 1992-07-09 1993-07-13 / TW272940B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4222534A DE4222534A1 (de) 1992-07-09 1992-07-09 Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura

Publications (1)

Publication Number Publication Date
TW272940B true TW272940B (en) 1996-03-21

Family

ID=6462826

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105551A TW272940B (en) 1992-07-09 1993-07-13 /

Country Status (12)

Country Link
US (1) US6248365B1 (zh)
EP (1) EP0585552B1 (zh)
JP (1) JP3776940B2 (zh)
KR (1) KR100300798B1 (zh)
AT (1) ATE231885T1 (zh)
AU (1) AU671835B2 (zh)
CA (1) CA2100212C (zh)
DE (2) DE4222534A1 (zh)
ES (1) ES2188586T3 (zh)
HU (1) HU220599B1 (zh)
MX (1) MX9304110A (zh)
TW (1) TW272940B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329030B1 (en) 2006-08-17 2008-02-12 Augux., Ltd. Assembling structure for LED road lamp and heat dissipating module

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
JP5137053B2 (ja) * 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
JP2008529536A (ja) * 2005-02-14 2008-08-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 加齢性黄斑変性を処置および診断するための方法および試薬
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US8703136B2 (en) * 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
DK2379066T3 (da) * 2008-09-16 2014-06-30 Imunek Farma Ilaç Sanayi Ve Ticaret A S Anvendelse af opioidantagonister til fremstilling af et lægemiddel til behandling af retinadegenerationssygdomme
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev METHOD FOR STIMULATING THE LIVER REGENERATION
TR201203732T1 (tr) * 2009-10-01 2012-09-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CA2799192A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
EP2758076B1 (en) 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
AU2012318275B2 (en) 2011-12-22 2016-05-19 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
ES2844189T3 (es) 2013-03-08 2021-07-21 Csl Behring Gmbh Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US10532087B2 (en) 2015-06-03 2020-01-14 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
AU2017305856A1 (en) 2016-08-05 2019-03-21 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
US20190183991A1 (en) 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
KR102060891B1 (ko) 2018-05-23 2019-12-30 유승선 가미사물탕을 유효성분으로 포함하는 색소성자반증 예방 또는 치료용 조성물
US20240000908A1 (en) 2020-11-20 2024-01-04 Csl Behring Gmbh Method for Treating Antibody-Mediated Rejection
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2617202A1 (de) * 1976-04-20 1977-11-03 Troponwerke Dinklage & Co Oligopeptide als komplementhemmer
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5157019A (en) * 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
EP0353941A3 (en) * 1988-08-02 1991-05-02 Takeda Chemical Industries, Ltd. Medicament for psoriasis containing derivatives of 3-aminopyrazolo [3,4-d]pyrimidine
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329030B1 (en) 2006-08-17 2008-02-12 Augux., Ltd. Assembling structure for LED road lamp and heat dissipating module

Also Published As

Publication number Publication date
JPH06157342A (ja) 1994-06-03
HU9301978D0 (en) 1993-09-28
HU220599B1 (hu) 2002-03-28
HUT65754A (en) 1994-07-28
CA2100212C (en) 2005-03-08
DE59310327D1 (de) 2003-03-06
KR940005285A (ko) 1994-03-21
US6248365B1 (en) 2001-06-19
EP0585552B1 (de) 2003-01-29
ES2188586T3 (es) 2003-07-01
KR100300798B1 (ko) 2001-10-22
DE4222534A1 (de) 1994-01-13
AU4180593A (en) 1994-01-13
CA2100212A1 (en) 1994-01-10
JP3776940B2 (ja) 2006-05-24
MX9304110A (es) 1994-03-31
AU671835B2 (en) 1996-09-12
ATE231885T1 (de) 2003-02-15
EP0585552A1 (de) 1994-03-09

Similar Documents

Publication Publication Date Title
TW272940B (en) /
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
AU3008092A (en) Novel use of modafinil
DE2862409D1 (en) Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders
ZA901854B (en) Pharmaceutical product for the treatment of immunoregulatory disorders
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
EP0651639A4 (en) METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS.
IL106776A0 (en) Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
EP0313654A4 (en) MEDICINAL PRODUCTS FOR PROPHYLAXIS AND TREATMENT OF LIVER DISEASES.
EP0182462A3 (en) Pressure relieving medical device suitable for the prophylaxis of pressure sores
AR243384A1 (es) Procedimiento para preparar composiciones farmaceuticas para la profilaxis y terapia de desordenes y enfermedades del tracto gastrointestinal del hombre y mamiferos en general.
AU2806692A (en) Medicament for the treatment of anxiety
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
EP0784983A3 (en) Use of extracellular hemoglobin
NO874241D0 (no) Terapeutisk aktive salter.
ZA947912B (en) Treatment of medical disorders associated with free radical formation
GB8912373D0 (en) Medicament for various skin and ulcer disorders
AU603375B2 (en) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
ZA944671B (en) Medicaments for the treatment of inflammatory diseases
ZA842958B (en) Benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
GB9413939D0 (en) Pharmaceutical composition for the treatment of chronic skin ulcers
PH25733A (en) 5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders
KR0149275B1 (en) Medicaments for the treatment of cerebral apoplexy

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees